Jieyang

People with end stage kidney disease (ESKD) who require dialysis have a much higher risk of developing cardiovascular disease compared to the general population, with heart problems causing over half of the deaths in this group. This trial is studying whether taking low dose aspirin daily can safely reduce cardiovascular events in these dialysis patients. The study is a Phase 4, multi-center, randomized controlled trial designed to provide clear evidence about aspirin's benefits and risks in this specific population, where existing data is limited. Participants will be randomly assigned to receive either a daily 100 mg aspirin tablet or a matching placebo. The trial uses the Chinese peritoneal dialysis and hemodialysis registry to efficiently screen and recruit patients and collect data during routine dialysis care. Follow-up visits occur every six months as part of regular clinical care, and the study will continue until enough cardiovascular events have occurred, expected to take about five years. During the study, participants will have their health monitored through routine clinic visits every six months, with data collected on cardiovascular events and safety. The main outcome measured is the number of participants experiencing major cardiovascular events over the study period. An independent board will oversee safety and study progress. The trial uses intention-to-treat analysis and aims to minimize participant burden by integrating study procedures into usual care.

Researchers are investigating treatments to eradicate Helicobacter pylori (HP), a bacteria linked to various diseases. While a 10-14 day quadruple therapy including bismuth is effective, it has drawbacks like severe side effects, high costs, and low patient compliance. This study focuses on a dual therapy using keverprazan, a new acid blocker that is stronger and longer-lasting than proton pump inhibitors (PPIs) and is not affected by genetic differences, combined with amoxicillin. The goal is to assess the effectiveness of different doses and durations of this therapy for eradicating HP infection. The study compares three treatment regimens: high-dose keverprazan with amoxicillin taken three times daily for 14 days; low-dose keverprazan with amoxicillin taken twice daily for 14 days; and high-dose keverprazan with amoxicillin taken three times daily for 10 days. Keverprazan hydrochloride tablets are given orally at 20 mg twice daily, while amoxicillin is given orally at 1000 mg either twice or three times daily depending on the group. These variations aim to optimize the treatment's effectiveness and patient compliance. Participants aged 18 to 75 who are HP positive or have failed previous HP eradication will be closely monitored during the study. Researchers will evaluate the HP eradication rate at 6 weeks after treatment. Participants will be assessed through clinical visits, laboratory tests, and adherence checks to treatment instructions. Safety and tolerance will also be monitored throughout the study to understand the therapy’s effects and any adverse reactions.